Bristol Myers Squibb, Johnson & Johnson halt major heart-drug trial after disappointing results

Johnson & Johnson gets FDA nod for new depression treatment

This approval is based on positive results from two Phase 3, global, double-blind, placebo-controlled trials

Johnson & Johnson’s Rybrevant shows 45% response rate in HNSCC

Based on these promising results, Johnson & Johnson plans to move the program into a Phase 3 trial to further investigate subcutaneous amivantamab

Johnson & Johnson submits additional data to FDA on psoriatic arthritis

The submission is supported by results from the Phase 3b APEX study

Johnson & Johnson launches new intraocular lens TECNIS PureSee in India

Next-generation lens features purely refractive design, delivering uninterrupted high-quality vision with high best-in-category contrast & low-light performance

Johnson & Johnson appoints Dr. John Reed as EVP, Pharmaceuticals, R&D

Johnson & Johnson MedTech India partners with Karkinos to upskill professionals in cancer care

To bring quality cancer treatment closer to patients, India’s leading MedTech brand is joining forces with the unique technology-led platform

Johnson & Johnson and Momenta Pharmaceuticals file lawsuit against NATCO Pharma

This lawsuit has been filed in the Pennsylvania Federal Court. NATCO and its marketing partner Mylan

Johnson & Johnson India launches ‘Be The Change For TB’ initiative

#BeTheChangeForTB is a public awareness initiative under the Corporate TB Pledge and aims to create a cadre of Youth Changemakers who can act as catalysts of change to help eliminate TB from India

Johnson & Johnson Vision Care receives USFDA approval for drug-eluting contact lens

Novel technology combines ACUVUE daily disposable contact lenses with an established antihistamine in FDA- first in its new category